CSL Behring, Durata, Novartis, Zalicus
CSL Behring's Hizentra cleared to treat PID in Japan . . . read more
Durata files NDA for ABSSSI treatment . . . read more
Zalicus gets orphan designation for Z160 . . . read more
Good data for Novartis' Lucentis . . . read more
Sign up now to receive the free weekly newsletter, and more!
The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.